

**APD351Hu01 100µg**  
**Active Interleukin 17 Receptor B (IL17RB)**  
**Organism Species: Homo sapiens (Human)**  
***Instruction manual***

FOR IN VITRO USE AND RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Asp61~Thr200

**Tags:** N-terminal His-tag

**Purity:** >80%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays; In vivo assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 8.9

**Predicted Molecular Mass:** 19.4kDa

**Accurate Molecular Mass:** 19kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.


**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## **[ SEQUENCE ]**

```
DYSILMNVSW VLRADASIRL LKATKICVTG KSNFQSYSCV  
RCNYTEAFQT QTRPSGGKWT FSYIGFPVEL NTVYFIGAHN IPNANMNEDG  
PSMSVNFTSP GCLDHIMKYK KKCVKAGSLW DPNITACKKN EETVEVNFTT
```


## **[ ACTIVITY ]**

IL17RB (Interleukin-17 receptor B) is a receptor for the proinflammatory cytokines IL17B (Interleukin-17B) and IL17E (Interleukin-17E). This receptor has been shown to mediate the activation of NF-kappaB and the production of IL8 induced by IL17E. Thus a binding ELISA assay was constructed to detect the association of recombinant human IL17RB with recombinant human IL17B. Briefly, IL17RB were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to IL17B-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-IL17RB pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of IL17RB with IL17B was shown in Figure 1 and this effect was in a dose dependent manner.




**Figure 1. The binding activity of IL17RB with IL17B.**

## **[ IDENTIFICATION ]**



**Figure 2. SDS-PAGE**

**Sample: Active recombinant IL17RB, Human**



**Figure 3. Western Blot**

**Sample: Recombinant IL17RB, Human;**

**Antibody: Rabbit Anti-Human IL17RB Ab (PAD351Hu01)**